达嘉维康 reported revenue of ¥2.70B for the period ended 2026-06-30, -0.2% year on year. Net income was ¥0.02B, a 0.8% net margin on a 18.3% gross margin. The largest revenue line is 药店零售 at 58% of the total. Free cash flow for the period was ¥0.07B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.70B | -0.2% |
| Gross profit | ¥0.49B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.02B | +52.0% |
| Gross margin | 18.3% | Net margin 0.8% |
| Revenue Q/Q | -4.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 药店零售 | ¥1.57B | 58.2% |
| 医药分销 | ¥1.04B | 38.6% |
| 药品生产收入 | ¥0.06B | 2.4% |
| 其他收入 | ¥0.02B | 0.6% |
| 医院收入 | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥2.21B | 81.7% |
| R&D | ¥0.01B | 0.2% |
| SG&A | ¥0.40B | 14.7% |
| Tax & other | ¥0.01B | 0.3% |
| Item | Amount |
|---|---|
| Total assets | ¥6.33B |
| Total liabilities | ¥4.71B |
| Shareholders' equity | ¥1.62B |
| Equity / assets | 25.6% |
| Operating cash flow | ¥0.08B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.07B |
| Cash conversion (OCF / net income) | 51% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
武汉天源 ・ 强瑞技术 ・ 瑞纳智能 ・ 西点药业 ・ 聚赛龙 ・ 满坤科技 ・ 金钟股份 ・ 瑞德智能 ・ 招标股份 ・ 哈焊华通 ・ 华研精机 ・ *ST元道
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies